Published on September 6, 2012 at 2:39 AM
Baxter International Inc. (NYSE:BAX) today announced that the company
has begun dosing patients with malignant solid tumors in a Phase I
clinical trial of a monoclonal antibody, representing the company's
efforts to extend its oncology portfolio with advanced biological
research and development.
The candidate is a fully-human, recombinant anti-MIF (anti-macrophage
migration inhibitory factor) monoclonal antibody with potential to be a
new therapeutic agent in treatment of cancer. Monoclonal antibodies
target a specific antigen in the body rather than traditional, systemic
regimens. The anti-MIF antibody targets the MIF protein, a protein that
induces inflammatory responses in the body and that has also been shown
to influence the growth and spread of tumors. By inhibiting the
cancer-promoting effects of MIF, the anti-MIF antibody may be capable of
restricting the growth of tumors.
''This research program leverages Baxter's scientific expertise in
systemic oncology therapies and leadership in biologics, and further
reinforces our commitment of supporting patients with life-threatening
conditions,'' said Ludwig Hantson, Ph.D., president of Baxter's
The Phase I, open label study is designed to assess the safety,
tolerability and optimal dose of the antibody in up to 44 adult patients
with malignant solid tumors. The ''all-comers'' design of the
single-agent trial will allow for expedited accrual of patients and
evaluation of safety and potential therapeutic activity in patients with
varied solid tumor types. The study will also investigate
pharmacokinetics (how the body absorbs and distributes the compound) and
changes in levels of markers that indicate anti-tumor activity.
Source: Baxter International Inc.